Metropolis Healthcare Q2 Profit Up 13% Driven by TruHealth and Specialty Tests

Metropolis Healthcare reported a 13% year-on-year rise in its net profit for the September 2025 quarter, supported by strong contributions from its TruHealth wellness and specialty test portfolios. The company’s net profit stood at ₹53 crore, compared with ₹47 crore in the same period last year. Revenue grew 22.7% year-on-year to ₹429 crore, highlighting consistent demand across its business segments.

Improved Operating Performance

Earnings before interest, tax, depreciation, and amortisation (EBITDA) increased 20.5% to ₹108.6 crore, compared with ₹90.1 crore a year earlier. The EBITDA margin stood at 25.3%, slightly lower than 25.7% in the previous year, mainly due to higher operational costs. 

The growth in patient and test volumes, up by 11% and 12% year-on-year respectively, indicated steady expansion in both its B2C and B2B segments, which recorded revenue growth of 16% and 33%.

Strong Contribution from Wellness and Specialty Portfolios

The company’s TruHealth wellness and specialty test portfolios played a key role in driving overall growth, with revenue increases of approximately 24% and 33% year-on-year, respectively. Rising demand for preventive and specialised testing continued to enhance revenue per patient and revenue per test, which rose by 11% and 10%.

Geographic Expansion and Subsidiary Performance

Metropolis Healthcare also expanded its regional presence, with North India’s contribution to total revenue increasing to 19%, up from 17% in the previous quarter. Tier III cities posted 13% growth, reflecting growing accessibility of diagnostic services in smaller towns. The Core Diagnostics segment achieved a positive profit after tax within two quarters of acquisition, and subsidiaries in Dehradun and Agra continued to perform well, maintaining margins above the company’s average.

Dividend Declaration and Market Reaction

The company declared an interim dividend of ₹4 per equity share for the financial year 2025–26, with a record date set for November 11, 2025. The dividend is expected to be credited or dispatched within 30 days of declaration.

Stock Performance and Market Outlook

Metropolis Healthcare Share Price ended at ₹2,031 as of November 4, 2025, marking a 1.31% increase from the previous close. The stock, listed under BSE: 542650 and NSE: METROPOLIS, has traded between ₹1,315 and ₹2,263 over the past year, reflecting stable investor sentiment. 

With a market capitalisation of about ₹10,524 crore, the company continues to maintain moderate profitability, supported by a P/E ratio of 69.2, a return on capital employed of 14.7%, and a return on equity of 11.5%.

Read More:Metropolis Healthcare Q3 FY25 Business Update Revenue Growth May Hit Double Digit Mark

Conclusion

Metropolis Healthcare’s second-quarter results highlight stable financial performance supported by growing demand for preventive and specialty diagnostics. With expanding regional presence, steady profitability, and a focus on innovation, the company remains well-positioned to benefit from India’s evolving healthcare landscape. The consistent rise in patient volumes and revenue growth reinforces its strength in the diagnostics segment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.